HomeCategoryResearch Archives -

https://mysicklefamilyllc.com/wp-content/uploads/2019/12/shutterstock_215498767_zpsmgsnucvk-1-1000x720.jpg

The National Institutes of Health (NIH) has awarded a grant to researchers at Carnegie Mellon University’s College of Engineering to support their project to develop a non-invasive, non-toxic and non-addictive pain treatment for people with sickle cell disease (SCD). “There is an urgent unmet need to develop safe, effective, and non-addictive device-based technologies to treat pain in sickle cell disease,” Bin He, PhD, said in a news story. Professor He is department head of Biomedical Engineering (BME) at the College...

https://mysicklefamilyllc.com/wp-content/uploads/2019/12/shutterstock_367352810_zpsax19alp3-1-1280x720.jpg

LentiGlobin, Bluebird Bio’s investigational gene therapy for sickle cell disease (SCD), continues to show promising results in SCD patients participating in the company’s Phase 1/2 HGB-206 clinical trial, according to the latest study data. The new findings — which included data from additional patients treated in the trial, updated data from those previously reported, and exploratory analyses — were presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition, held Dec. 6-10...

https://mysicklefamilyllc.com/wp-content/uploads/2019/11/shutterstock_494829118-1.jpg

Droplets packed with hemoglobin may briefly form tiny clusters inside red blood cells that ultimately deform their shape, and cause the pain crises that mark sickle cell disease (SCD), a study reports. The research, “A mechanism for reversible mesoscopic aggregation in liquid solutions,” appeared in the journal Nature Communications. In people with SCD, hemoglobin (the protein in red blood cells that carries oxygen) can form rigid protein strands in the blood cells that alter their shape. These...